Sandoz biosimilar expansion to initially rely on external assets
Sandoz plans to expand its biosimilar-drug portfolio over the next decade and a half, with the initial push relying on external assets, according to J.P. Morgan analysts.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.